Sandoz launches Phase III clinical trial for biosimilar etanercept PipelineReview.com (press release) HOLZKIRCHEN, Germany I June 24, 2013 I Sandoz, the global leader in biosimilars, announced it has initiated a major Phase III clinical trial with its biosimilar version of etanercept (Amgen's Enbrel ®). The global clinical trial will seek to confirm ... |
